tiprankstipranks
Privia Health Group (PRVA)
NASDAQ:PRVA
US Market
PRVA
Privia Health Group
RESEARCH TOOLSreports
Want to see PRVA full AI Analyst Report?

Privia Health Group (PRVA) Stock Forecast & Price Target

215 Followers
See the Price Targets and Ratings of:

PRVA Analyst Ratings

Strong Buy
15Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Privia
Health Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRVA Stock 12 Month Forecast

Average Price Target

$31.54
▲(31.31% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Privia Health Group in the last 3 months. The average price target is $31.54 with a high forecast of $36.00 and a low forecast of $25.00. The average price target represents a 31.31% change from the last price of $24.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","22":"$22","27":"$27","32":"$32","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,22,27,32,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.07,22.21846153846154,23.366923076923076,24.515384615384615,25.663846153846155,26.81230769230769,27.96076923076923,29.10923076923077,30.25769230769231,31.406153846153845,32.55461538461539,33.70307692307692,34.85153846153846,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.07,21.875384615384615,22.68076923076923,23.486153846153847,24.29153846153846,25.096923076923076,25.90230769230769,26.707692307692305,27.513076923076923,28.318461538461538,29.123846153846152,29.92923076923077,30.73461538461538,{"y":31.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.07,21.372307692307693,21.674615384615386,21.97692307692308,22.279230769230768,22.58153846153846,22.883846153846154,23.186153846153847,23.48846153846154,23.790769230769232,24.09307692307692,24.395384615384614,24.697692307692307,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$36.00Average Price Target$31.54Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on PRVA
Ryan Halsted
RBC Capital
RBC Capital
$31
Buy
29.06%
Upside
Reiterated
04/15/26
RBC Capital Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Evercore ISI Analyst forecast on PRVA
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$30→$26
Buy
8.24%
Upside
Reiterated
04/08/26
Privia Health price target lowered to $26 from $30 at Evercore ISIPrivia Health price target lowered to $26 from $30 at Evercore ISI
Truist Financial Analyst forecast on PRVA
Jailendra Singh
Truist Financial
Truist Financial
$33
Buy
37.39%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Nuvalent (NASDAQ: NUVL) and Tonix Pharma (NASDAQ: TNXP)
Barclays Analyst forecast on PRVA
Andrew Mok CFA
Barclays
Barclays
$23→$25
Hold
4.08%
Upside
Reiterated
03/25/26
Privia Health price target raised to $25 from $23 at BarclaysPrivia Health price target raised to $25 from $23 at Barclays
Piper Sandler Analyst forecast on PRVA
Jessica Tassan
Piper Sandler
Piper Sandler
$36
Buy
49.88%
Upside
Reiterated
03/19/26
Piper Sandler Reaffirms Their Buy Rating on Privia Health Group (PRVA)
J.P. Morgan Analyst forecast on PRVA
Lisa Gill
J.P. Morgan
J.P. Morgan
$35
Buy
45.71%
Upside
Reiterated
03/06/26
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA)
BTIG Analyst forecast on PRVA
Unknown Analyst
BTIG
Not Ranked
BTIG
$35
Buy
45.71%
Upside
Reiterated
03/05/26
BTIG Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Citi Analyst forecast on PRVA
Daniel Grosslight
Citi
Citi
$34→$32
Buy
33.22%
Upside
Reiterated
03/03/26
Privia Health price target lowered to $32 from $34 at CitiPrivia Health price target lowered to $32 from $34 at Citi
Canaccord Genuity Analyst forecast on PRVA
Richard Close
Canaccord Genuity
Canaccord Genuity
$34→$35
Buy
45.71%
Upside
Reiterated
02/27/26
Privia Health price target raised to $35 from $34 at CanaccordPrivia Health price target raised to $35 from $34 at Canaccord
KeyBanc Analyst forecast on PRVA
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)
Jefferies Analyst forecast on PRVA
Jack Slevin
Jefferies
Jefferies
$30→$32
Buy
33.22%
Upside
Reiterated
02/26/26
Analysts Are Bullish on Top Healthcare Stocks: Kymera Therapeutics (KYMR), Privia Health Group (PRVA)
William Blair Analyst forecast on PRVA
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), Agilon Health (NYSE: AGL) and Privia Health Group (NASDAQ: PRVA)
TD Cowen Analyst forecast on PRVA
Ryan Langston
TD Cowen
TD Cowen
$30
Buy
24.90%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA) and Ramsay Health Care (Other OTC: RMSYF)
Needham Analyst forecast on PRVA
Matthew Shea
Needham
Needham
$30
Buy
24.90%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Trulieve Cannabis (Other OTC: TCNNF) and Privia Health Group (NASDAQ: PRVA)
BMO Capital Analyst forecast on PRVA
Sean Dodge
BMO Capital
BMO Capital
$30
Buy
24.90%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Disc Medicine (NASDAQ: IRON) and Warby Parker (NYSE: WRBY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on PRVA
Ryan Halsted
RBC Capital
RBC Capital
$31
Buy
29.06%
Upside
Reiterated
04/15/26
RBC Capital Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Evercore ISI Analyst forecast on PRVA
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$30→$26
Buy
8.24%
Upside
Reiterated
04/08/26
Privia Health price target lowered to $26 from $30 at Evercore ISIPrivia Health price target lowered to $26 from $30 at Evercore ISI
Truist Financial Analyst forecast on PRVA
Jailendra Singh
Truist Financial
Truist Financial
$33
Buy
37.39%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Nuvalent (NASDAQ: NUVL) and Tonix Pharma (NASDAQ: TNXP)
Barclays Analyst forecast on PRVA
Andrew Mok CFA
Barclays
Barclays
$23→$25
Hold
4.08%
Upside
Reiterated
03/25/26
Privia Health price target raised to $25 from $23 at BarclaysPrivia Health price target raised to $25 from $23 at Barclays
Piper Sandler Analyst forecast on PRVA
Jessica Tassan
Piper Sandler
Piper Sandler
$36
Buy
49.88%
Upside
Reiterated
03/19/26
Piper Sandler Reaffirms Their Buy Rating on Privia Health Group (PRVA)
J.P. Morgan Analyst forecast on PRVA
Lisa Gill
J.P. Morgan
J.P. Morgan
$35
Buy
45.71%
Upside
Reiterated
03/06/26
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA)
BTIG Analyst forecast on PRVA
Unknown Analyst
BTIG
Not Ranked
BTIG
$35
Buy
45.71%
Upside
Reiterated
03/05/26
BTIG Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Citi Analyst forecast on PRVA
Daniel Grosslight
Citi
Citi
$34→$32
Buy
33.22%
Upside
Reiterated
03/03/26
Privia Health price target lowered to $32 from $34 at CitiPrivia Health price target lowered to $32 from $34 at Citi
Canaccord Genuity Analyst forecast on PRVA
Richard Close
Canaccord Genuity
Canaccord Genuity
$34→$35
Buy
45.71%
Upside
Reiterated
02/27/26
Privia Health price target raised to $35 from $34 at CanaccordPrivia Health price target raised to $35 from $34 at Canaccord
KeyBanc Analyst forecast on PRVA
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)
Jefferies Analyst forecast on PRVA
Jack Slevin
Jefferies
Jefferies
$30→$32
Buy
33.22%
Upside
Reiterated
02/26/26
Analysts Are Bullish on Top Healthcare Stocks: Kymera Therapeutics (KYMR), Privia Health Group (PRVA)
William Blair Analyst forecast on PRVA
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), Agilon Health (NYSE: AGL) and Privia Health Group (NASDAQ: PRVA)
TD Cowen Analyst forecast on PRVA
Ryan Langston
TD Cowen
TD Cowen
$30
Buy
24.90%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA) and Ramsay Health Care (Other OTC: RMSYF)
Needham Analyst forecast on PRVA
Matthew Shea
Needham
Needham
$30
Buy
24.90%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Trulieve Cannabis (Other OTC: TCNNF) and Privia Health Group (NASDAQ: PRVA)
BMO Capital Analyst forecast on PRVA
Sean Dodge
BMO Capital
BMO Capital
$30
Buy
24.90%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Disc Medicine (NASDAQ: IRON) and Warby Parker (NYSE: WRBY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Privia Health Group

3 Months
xxx
Success Rate
6/10 ratings generated profit
60%
Average Return
+2.74%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.74% per trade.
1 Year
Constantine DavidesCitizens JMP
Success Rate
10/11 ratings generated profit
91%
Average Return
+8.02%
reiterated a buy rating 6 months ago
Copying Constantine Davides's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +8.02% per trade.
2 Years
xxx
Success Rate
10/11 ratings generated profit
91%
Average Return
+10.10%
reiterated a xxx
 rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +10.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRVA Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
2
3
Buy
22
23
38
61
65
Hold
10
10
21
32
32
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
33
59
95
100
In the current month, PRVA has received 68 Buy Ratings, 32 Hold Ratings, and 0 Sell Ratings. PRVA average Analyst price target in the past 3 months is 31.54.
Each month's total comprises the sum of three months' worth of ratings.

PRVA Financial Forecast

PRVA Earnings Forecast

Next quarter’s earnings estimate for PRVA is $0.07 with a range of $0.04 to $0.12. The previous quarter’s EPS was $0.07. PRVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRVA is $0.07 with a range of $0.04 to $0.12. The previous quarter’s EPS was $0.07. PRVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.

PRVA Sales Forecast

Next quarter’s sales forecast for PRVA is $559.60M with a range of $531.20M to $585.51M. The previous quarter’s sales results were $541.17M. PRVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.
Next quarter’s sales forecast for PRVA is $559.60M with a range of $531.20M to $585.51M. The previous quarter’s sales results were $541.17M. PRVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.

PRVA Stock Forecast FAQ

What is PRVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Privia Health Group’s 12-month average price target is 31.54.
    What is PRVA’s upside potential, based on the analysts’ average price target?
    Privia Health Group has 31.31% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRVA a Buy, Sell or Hold?
          Privia Health Group has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Privia Health Group’s price target?
            The average price target for Privia Health Group is 31.54. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $36.00 ,the lowest forecast is $25.00. The average price target represents 31.31% Increase from the current price of $24.02.
              What do analysts say about Privia Health Group?
              Privia Health Group’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of PRVA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.